Post Reply
1-20 of 1197
Trendlines portfolio company Phytolon closes US$23.6 mil Series B financing
The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, Phytolon, has closed its US$23.6 million Series B financing to commercialise its natural food colours in the United States.
Trendlines says that the Series B financing round for Phytolon was led by a strategic investor, whose identity has not yet been disclosed.
&ldquo This funding was structured in three stages, including the realization of SAFE investment vehicles made prior to this closing, with the bulk of the capital being secured during the final stage earlier this month. In addition to the lead investor, existing investors also participated in the round,&rdquo Trendlines add.
From Trendlines&rsquo point of view, the entry of a strategic lead investor at the commercialisation stage is a positive development for Phytolon.
&ldquo We believe this financing significantly strengthens Phytolon&rsquo s growth trajectory and long-term value creation potential. Trendlines and Consensus Business Group remain committed long-term shareholders of Phytolon,&rdquo says Trendlines&rsquo executive director and CEO, Haim Brosh.
Shares of Trendlines closed 0.3 cents higher, or 5.26% up at 6 cents on May 28.
That depends on whether you are trading or holding for EXITs
TraderBen ( Date: 29-May-2026 09:14) Posted:
| this one sai one la.. alwways gap up and sell down one.. |
|
this one sai one la.. alwways gap up and sell down one..
Trendlines Portfolio Company Phytolon Closes US$23.6 Million Series B to Commercialize its Innovative Natural Food Colors
&bull The 3-stage financing round was led by a strategic investor as demand for high quality natural colors accelerates globally &bull Earlier this year the FDA approved ' Beetroot Red' , Phytolon' s first product made by fermentation the effective date is subjected to FDA procedures Misgav, Israel &ndash 28 May 2026 &ndash The Trendlines Group Ltd. (SGX: 42T OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, is pleased to announce that portfolio company Phytolon Ltd. (&ldquo Phytolon&rdquo ), a biotechnology company pioneering fermentation-based natural color solutions, has announced the close of its US$23.6 Million Series B financing to commercialize its natural food colors in the United States. The round reflects growing market demand for highperforming, economic, and sustainable natural substitution to synthetic dyes.
$0.062-$0.063....time to accumulate.
This one risks vs returns is now in the returns' favours as more of its startups starts to reach commercialization stage.
Any buyouts or commercial tieups will see massive upswings in its share price.
This one looks unusually strong today. Usually will spike up then die off.
Today seems to be holding well so far. $0.065 +$0.003 Vol 14.4 mil
&ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines.SmallSmall ( Date: 05-May-2026 08:15) Posted:
Trendlines portfolio company Vensica Medical&rsquo s needle-free bladder therapy progress into Phase two of clinical trial
The study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB). Photo: Bloomberg
The Trendlines Group Trendlines announced that its portfolio company, Vensica Medical, has secured the clearance from the US Food Drug Administration (FDA) on its investigational new drug (IND) application to initiate a Phase two clinical trial of ViXe.
According to Trendlines, the study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB).
Trendlines believes that the Phase two study will enrol approximately 210 patients across United States and Europe and this milestone triggers a contractual development milestone payment from its strategic partners.
Vensica Medical is supported by numerous investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines.
&ldquo We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare,&rdquo says Vensica Medical&rsquo s CEO, Avner Geva.
&ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines.
|
|
BBs try 70s series? Trade with care.
Trendlines portfolio company Vensica Medical&rsquo s needle-free bladder therapy progress into Phase two of clinical trial
The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, Vensica Medical, has secured the clearance from the US Food Drug Administration (FDA) on its investigational new drug (IND) application to initiate a Phase two clinical trial of ViXe.
According to Trendlines, the study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB).
Trendlines believes that the Phase two study will enrol approximately 210 patients across United States and Europe and this milestone triggers a contractual development milestone payment from its strategic partners.
Vensica Medical is supported by numerous investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines.
&ldquo We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare,&rdquo says Vensica Medical&rsquo s CEO, Avner Geva.
&ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines.
Shares in Trendlines closed flat at 6.2 cents on May 4.
Trendlines portfolio company Vensica Medical&rsquo s needle-free bladder therapy progress into Phase two of clinical trial
The study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB). Photo: Bloomberg
The Trendlines Group Trendlines announced that its portfolio company, Vensica Medical, has secured the clearance from the US Food Drug Administration (FDA) on its investigational new drug (IND) application to initiate a Phase two clinical trial of ViXe.
According to Trendlines, the study will evaluate Vensica&rsquo s Vibe ultrasound-based, needle-free drug delivery system in combination with Xeomin for the treatment of overactive bladder (OAB).
Trendlines believes that the Phase two study will enrol approximately 210 patients across United States and Europe and this milestone triggers a contractual development milestone payment from its strategic partners.
Vensica Medical is supported by numerous investors and strategic partners, including Merz Pharma, Laborie, Israel Biotech Fund and Trendlines.
&ldquo We believe ViXe has the potential to overcome the barriers of needle-based delivery and deliver meaningful impact in urologic healthcare,&rdquo says Vensica Medical&rsquo s CEO, Avner Geva.
&ldquo This clearance represents a key milestone in Vensica Medical&rsquo s development and follows a number of key developments recently in our portfolio, emphasising the progress and maturity of our companies,&rdquo adds Haim Brosh, CEO of Trendlines.
Imagine when as a chocolate manufacturer you have control over price of cocoa, control over production, control over not needing to rely on expensive transport, etc. basivally it will lead to predicatble cost in your supply chain and this will lead to higher productivity and profits. just one scenario. This ofcourse will bot replace the supply of natural cocoa in the medium term but in the long term the implications can be huge.
bechaotic ( Date: 22-Apr-2026 11:55) Posted:
This chocolate-cultured bar - how will it affect other chocolate manufacturers like Delfi Ltd?
|
|
The Trendlines Group&rsquo s Company Vensica Medical Advances Needle-Free
Bladder Therapy to Phase 2
&bull
Vensica received FDA IND clearance to initiate Phase 2 study of ViXe, its needle-free
Xeomin® delivery system for overactive bladder.
&bull
Strategic milestone validates clinical rationale for needle-free delivery and triggers
milestone payment from strategic partners.
&bull
ViXe aims to transform the standard of care for 33 million Americans living with overactive
bladder through a non-invasive ultrasound-based solution.
&bull
The Group holds approximately 9% in Vensica, founded by Avner Geva and incubated by
Trendlines.
This chocolate-cultured bar - how will it affect other chocolate manufacturers like Delfi Ltd?
Trendlines portfolio company Celleste Bio introduces world&rsquo s first milk chocolate bars with cell-cultured cocoa butter
The Trendlines Group (Trendlines) (SGX:42T) announced that its portfolio company, Celleste Bio, successfully produce the world&rsquo s first milk chocolate bars made with real cocoa butter using cell suspension culture technology.
Major multinational snack company, Mondelē z International, used the cocoa butter from Celleste Bio to produce almost 12 chocolate bars that met its product standards.
According to Trendlines, Celleste Bio intends to transform the chocolate market by using AI modelling to tailor cocoa butter for specific melting points and flavour profiles, giving manufacturers a boost in innovation and competitiveness.
Meanwhile, Celleste Bio is developing a resilient supply chain by achieving commercial-scale cocoa butter production in a 1000-liter bioreactor using only a single cocoa bean.
Trendlines claims that this process eliminates the sole dependence on the traditional farming of cocoa trees and supplements production, without replacing it.
&ldquo This milestone demonstrates Celleste Bio' s cell cultured ingredients are bio-identical to conventionally grown cocoa - meaning they deliver the same texture, melt profile and sensory experience, and sets the stage for scaling production to market-ready quantities in the foreseeable future,&rdquo says Haim Brosh, Trendlines&rsquo CEO.
Dare to put the sell queues means there will be BBs dare to clear. Retailers if can?t keep better stay away. Trade with care.
newbie1118 ( Date: 22-Apr-2026 10:56) Posted:
Seems like game over.
eric998 ( Date: 22-Apr-2026 10:35) Posted:
| Near lunch or after lunch? Today 70s series? |
|
|
|
The buy queue can be fake queue. Pretty scary.
Seems like game over.
eric998 ( Date: 22-Apr-2026 10:35) Posted:
Near lunch or after lunch? Today 70s series?
newbie1118 ( Date: 22-Apr-2026 10:07) Posted:
|
|
|
Near lunch or after lunch? Today 70s series?
newbie1118 ( Date: 22-Apr-2026 10:07) Posted:
|
Short squeeze later?
70 series coming?
TRENDLINES' s World First: Chocolate Made With Cocoa Butter From a Lab
Leong Chan Teik
22 April 2026
Imagine biting into a rich, velvety piece of milk chocolate that tastes exactly like your favorite brand, but was produced in a lab.
It is already a reality -- and a world first, according to Singapore-listed The Trendlines Group which holds a 17% stake in Celleste Bio which it helped found and incubate.
It has just announced a milestone for Celleste Bio: the unveiling of the world&rsquo s first milk chocolate bars made with cell-cultured cocoa butter.
This product matches the texture, melt profile, and sensory experience of the chocolate we&rsquo ve known for years.
 |
How Does " Lab-Grown" Chocolate Work?
|
Celleste Bio uses proprietary cell suspension culture technology. In simple terms, cells from a high-quality cocoa bean are grown in a controlled environment.
Trendlines stock price
|
5.6 c
|
52-wk range
|
2.6 &ndash 8.4 c
|
PE (ttm)
|
27
|
Market cap
|
S$81.5 m
|
Shares outstanding
|
1.46 B
|
Dividend
yield
|
--
|
1-yr return
|
70%
|
P/B
|
0.82
|
Source: Yahoo!
|
Celleste can produce enough chocolate-grade cocoa butter for chocolate bars using only a single cocoa bean.
The Trendlines press release says Celleste intends to " transform the chocolate market by using AI modelling to tailor cocoa butter for specific melting points and flavour profiles" .
Over the past three years, Celleste has validated its cultured cocoa butter as a direct alternative, and established a pilot facility for scaling production.
In a show of confidence, Mondelē z International, the maker of Cadbury and Toblerone, acted as a strategic and design partner, using Celleste&rsquo s cocoa butter to produce almost 12 chocolate bars that met its rigorous product standards.
 " This milestone demonstrates Celleste' s cell cultured ingredients are bio-identical to conventionally grown cocoa - meaning they deliver the same texture, melt profile and sensory experience, and sets the stage for scaling production to market-ready quantities in the foreseeable future."
-- Haim Brosh, CEO, Trendlines Group |
What This May Mean for Cocoa Prices
|
Traditional cocoa farming will come under pressure. Celleste&rsquo s technology introduces a resilient supply chain by achieving commercial-scale production in a 1,000-liter bioreactor using a single cocoa bean.
This process " eliminates the sole dependence on the traditional farming of cocoa trees and supplements production, without replacing it," says Trendlines.
By moving production to controlled facilities, the industry can create a buffer against the sharp price spikes we see when traditional harvests fail.
Will chocolates get cheaper?
It' s too early to tell. With market-ready cultured cocoa butter anticipated by 2027, the goal is commercial viability.
Because cell-cultured cocoa isn' t dependent on the weather, it offers a way to bypass the supply shocks that drive up the price of chocolates.
For chocolate makers, this is a game-changer. Manufacturers can now access a replacement that " preserves the quality and functionality that chocolate makers and consumers depend on" .
With US$5.6 million already raised from investors&mdash including Mondelē z International and The Trendlines Group&mdash Celleste Bio is moving fast.
As Trendlines CEO Haim Brosh stated, this milestone " sets the stage for scaling production to market-ready quantities in the foreseeable future" .
We are standing at the edge of a " chocolate revolution" that ensures sustainable growth without harming natural resources. |
